Distribution of the spotted-wing drosophila (Drosophila suzukii) in the north-eastern part of the Carpathian lowlands

L

Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.

The activity of ADAMTS13, the von Willebrand factor (VWF) cleaving protease is low in several conditions, including HELLP (haemolysis, elevated liver enzymes, and low platelet count) syndrome. As HELLP syndrome develops in most cases on the basis of preeclampsia, our aim was to determine whether plasma ADAMTS13 activity is decreased in preeclampsia. Sixty-seven preeclamptic patients, 70 healthy pregnant women and 59 healthy non-pregnant women were involved in this case-control study. Plasma ADAMTS13 activity was determined with the FRETS-VWF73 assay, while VWF antigen (VWF:Ag) levels with an enzyme-linked immunosorbent assay. The multimeric pattern of VWF was analyzed by SDS-agarose gel electrophoresis. There was no significant difference in plasma ADAMTS13 activity between the preeclamptic and the healthy pregnant and non-pregnant groups (median [25-75 percentile]: 98.8 [76.5-112.8] %, 96.3 [85.6-116.2] % and 91.6 [78.5-104.4] %, respectively; p > 0.05). However, plasma VWF:Ag levels were significantly higher in preeclamptic patients than in healthy pregnant and non-pregnant women (187.1 [145.6-243.1] % versus 129.3 [105.1-182.8] % and 70.0 [60.2-87.3] %, respectively; p < 0.001). The multimeric pattern of VWF was normal in each group. Primiparas had lower plasma ADAMTS13 activity than multi-paras (92.6 [75.8-110.6] % versus 104.2 [92.1-120.8] %; p = 0.011). No other relationship was found between clinical characteristics, laboratory parameters and plasma ADAMTS13 activity in either study group. In conclusion, plasma ADAMTS13 activity is normal in preeclampsia despite the increased VWF:Ag levels. However, further studies are needed to determine whether a decrease in plasma ADAMTS13 activity could predispose preeclamptic patients to develop HELLP syndrome

Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure.

Decreased activity of ADAMTS13, the von Willebrand factor (VWF) cleaving protease, was recently reported in cardiovascular diseases and in hepatic failure. Chronic heart failure (CHF) is characterised by abnormalities of left ventricular function accompanied by the failure of the liver and dysregulation of endothelial activation. Therefore, the aim of our study was to measure ADAMTS13 activity in CHF, and determine the prognostic value of VWF and ADAMTS13 on major clinical events in CHF. ADAMTS13 activity (measured by FRETS-VWF73 substrate) was decreased in CHF (n = 152, left ventricular ejection fraction <45%), and it correlated negatively with B-type natriuretic peptide (BNP) NYHA (New York Heart Association) classes, markers of synthetic capacity of the liver and endothelial dysfunction (all p < 0.005). Both, high VWF:Ag levels (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.189-1.943), and low ADAMTS13/VWF:Ag ratios (HR 0.70, 95% CI 0.58-0.84) independently and significantly predicted short-term (1 year follow-up) clinical adverse events in heart failure (HF). Decreased activity of ADAMTS13 with concomitant high VWF:Ag levels is a significant independent predictor of clinical events in CHF. The levels of the two molecules may integrate the impaired synthetic capacity of the liver and the disturbed endothelial regulation and can therefore be a useful tool to predict clinical events in CHF

Circulating mitochondrial stress 70 protein/mortalin and cytosolic Hsp70 in blood: Risk indicators in colorectal cancer.

Mitochondrial mortalin and cytosolic Hsp70 are essential chaperones overexpressed in cancer cells. Our goals were to reproduce our earlier findings of elevated circulating levels of mortalin and Hsp70 in colorectal cancer (CRC) patients with a larger patient cohort, to compare death risk assessment of mortalin, Hsp70, CEA and C19-9 and to assess their prognostic value in various CRC stages. Mortalin, Hsp70, CEA and CA19-9 levels were determined in sera of 235 CRC patients enrolled in the study and followed up 5 years after surgery. Association between their concentrations and patients' survival was analyzed by Kaplan-Meier estimator and subjected to Cox Proportional hazards analysis. Serum level of mortalin was independent of that of Hsp70, CEA and CA19-9, whereas Hsp70 level weakly correlated with CEA and CA19-9 levels. Improved short-term survival was found in early or advanced disease stages associated with lower mortalin and Hsp70 levels. Cox regression analysis showed a high mortality hazard (HR = 3.7, p < 0.001) in patients with both high mortalin and Hsp70 circulating levels. Multivariate analysis showed that high mortalin and Hsp70 significantly enhances risk score over a baseline model of age, number of affected lymph nodes, CEA, CA19-9, disease stage and perioperative therapy. Analysis of mortalin and Hsp70 in CRC patients' sera adds a high prognostic value to TNM stage and to CEA and CA19-9 and identifies patients with lower or higher survival probability in all CRC stages. Determination of mortalin and Hsp70 in blood could be a useful additive prognostic tool in guiding clinical management of patients

Analysis of interactions between inflammatory and vasoregulatory pathways in chronic heart failure: application of logical analysis of data, a novel data-mining tool = Analysis of interactions between inflammatory and vasoregulatory pathways in chronic heart failure: application of logical analysis of data, a novel data-mining tool

Pályázatunk keretein belül a következő feladatokat valósítottuk meg: 1, Klinikai vizsgálatokat tervezetünk és kiviteleztünk szívelégtelenségben, tüdőgyulladás eredetű szepszisben, preeclampsiában és colorectalis carcinomában szenvedő betegek bevonásával. Vizsgálataink során többféle biomarker, genetikai polimorfizmus és alap klinikai adat mérésére és rögzítésére került sor. Méréseink eredményeiről szakkcikkekben és doktori disszertációkban számoltink be, valamint egy szabadalom bejelentésére is sor kerül. A klinikai vizsgálatok során felépített adatbázisok képezték további elemzéseink és vizsgálataink alapját. 2, Az ELTE Operációkutatási Tanszék munkatársai által fejlesztett logikai adatanalízis algoritmus továbbfejlesztésére és valós adatokon történő kipróbálására került sor a szívelégtelenség adatbázis elemzésével. A futtatások eredményeit elemezve kiválasztottuk a legkedvezőbb predikciós jellemzőket mutató változó kombinációkat. Jellemző módon azt találtuk, hogy a leghatékonyabb prediktív kombinációk tartalmazzák az ismert klinikai prediktorokat (gyulladás, veseelégtelenség), azonban nem, vagy elvétve tartalamzzák az ezekkel kapcsolatos genetikai változékonyságot jelző polimorfizmusadatokat. 3, In vitro validálsái modellkísérleteket végeztünk az adatanalízissel megállapított prediktor kombinációk valós biológiai hatásainak elemzésére. Megállapítottuk, hogy önállóan, vagy kombinációban alkalmazva a kiváklasztott biomarkerek nem mutatnak kapcsolatot az endothel diszfunkció paramétereivel. | The following tasks were implemented within the framework of this project: 1, Clinical studies enrolling patients with chronic heart failure, pneumonia-associated sepsis, preeclampsia and colorectal cancer were planned and carried out. Several biomarkers, genetic markers and clinical data were measured or registered. Results of the project were published in multiple original artoicles in international peer-reviewed journals and formed the basis of PhD thesis and patent submission. In-depth statistical and mathematical analysis of study databases were also also done. 2, In collaboration with researchers at the ELTE Department of Operation research, amendement and testing of the logical analysis of data algorithm was done with real data. Analysing the results of the different runs variable patterns with good discriminating and predicting power were selected. Typically, the best marker combinations contained the well known clinical predictors in CHF, including markers of renal failure, infalmmation and vasoregulation. However, markers of genetic variability of these biomarkrs occured unlikely in the best patterns. 3, In validation experiments using endothelial cell cultures we aimed to show biological effects of the selected biomarker combinations. It was determined that the selected clinical biomarkers neither alone, nor in combination were able to induce endothelial disfunction

Tyrosine kinase inhibitor Imatinib mesylate alters DMBA-induced early onco/suppressor-gene expression with tissue-specificity in mice

L

DNA methylation clock DNAmFitAge shows regular exercise is associated with slower aging and systemic adaptation

DNAmPhenoAge, DNAmGrimAge, and the newly developed DNAmFitAge are DNA methylation (DNAm)-based biomarkers that reflect the individual aging process. Here, we examine the relationship between physical fitness and DNAm-based biomarkers in adults aged 33–88 with a wide range of physical fitness (including athletes with long-term training history). Higher levels of VO 2 max ( ρ = 0.2, p = 6.4E − 4, r = 0.19, p = 1.2E − 3), Jumpmax ( p = 0.11, p = 5.5E − 2, r = 0.13, p = 2.8E − 2), Gripmax ( ρ = 0.17, p = 3.5E − 3, r = 0.16, p = 5.6E − 3), and HDL levels ( ρ = 0.18, p = 1.95E − 3, r = 0.19, p = 1.1E − 3) are associated with better verbal short-term memory. In addition, verbal short-term memory is associated with decelerated aging assessed with the new DNAm biomarker FitAgeAcceleration ( ρ : − 0.18, p = 0.0017). DNAmFitAge can distinguish high-fitness individuals from low/medium-fitness individuals better than existing DNAm biomarkers and estimates a younger biological age in the high-fit males and females (1.5 and 2.0 years younger, respectively). Our research shows that regular physical exercise contributes to observable physiological and methylation differences which are beneficial to the aging process. DNAmFitAge has now emerged as a new biological marker of quality of life

Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state.

Here we validate the strong, independent prediction of morbidity and mortality in HF by RDW. The described correlations between RDW and inflammation, ineffective erythropoiesis, undernutrition, and impaired renal function may facilitate the understanding why this marker is associated with adverse outcomes in HF